Home » Archive

Marketwire, News, Syndication »

Quidel Receives CE Mark for Its Molecular Diagnostic Test for Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV)

Posted by Mary Canady March 12th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 12, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cell-based virology assays, announced today that it has received the CE Mark for the Quidel MolecularT RSV +…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Prepares to Continue iSONEP Trials in August

Posted by Mary Canady March 12th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 12, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, plans to manufacture new antibody drug substance in preparation for the continuation of its PEDigree and Nexus tri…

More...

Marketwire, News, Syndication »

Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2011 Financial Results

Posted by Mary Canady March 9th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 9, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and ann…

More...

Marketwire, News, Syndication »

Cytori Provides Strategic Outlook, Near Term Objectives and Reports Year-End 2011 Results

Posted by Mary Canady March 8th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 8, 2012) – In 2011, Cytori Therapeutics (NASDAQ: CYTX) achieved important objectives towards validating Celution┬« technology in multiple large market indications, clarified the U.S. cardiovascular pathway with FDA, …

More...

Marketwire, News, Syndication »

Medistem Signs Exclusive Worldwide License With Yale University for Treatment of Type 1 Diabetes Using Stem Cells

Posted by Mary Canady March 7th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 7, 2012) – Medistem Inc. (PINKSHEETS: MEDS) and Yale University have signed an exclusive worldwide licensing agreement covering the generation of pancreatic islets from stem cells such as the Endometrial Regenerative…

More...

Marketwire, News, Syndication »

Medistem Signs Exclusive Worldwide License With Yale University for Treatment of Type 1 Diabetes Using Stem Cells

Posted by Mary Canady March 7th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 7, 2012) – Medistem Inc. (PINKSHEETS: MEDS) and Yale University have signed an exclusive worldwide licensing agreement covering the generation of pancreatic islets from stem cells such as the Endometrial Regenerative…

More...

Marketwire, News, Syndication »

Senomyx to Webcast Corporate Presentation at the ROTH 24th Annual OC Growth Stock Conference

Posted by Mary Canady March 7th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 7, 2012) – Senomyx, Inc. (NASDAQ: SNMX), a leading company focused on using proprietary taste receptor technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply indus…

More...

Drug Development, Drug Discovery, Headline, SDBN Blog, SDBN Events »

SDBN March 26th 2012 Event with Organovo

Posted by Mary Canady March 6th, 2012 .
No Comments

Organovo is an exciting San Diego biotech company with technology to create human tissue through a technique called 3D bioprinting. The tissue can be used for drug discovery and development, and the company has been included in the MIT Technology Review’s 2012 TR50 list of the world’s most innovative companies. The excitement around Organovo has grown since they recently announced funding and their stock is now publicly traded. You’ll get the chance to hear from CEO Keith Murphy at our March 26th event, he’ll give a presentation titled ‘3D Bioprinting …

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Raises $9.3 Million in Equity Financing

Posted by Mary Canady March 6th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 6, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has entered into subscription agreements with various investors to raise approximately $9.3 million through the sal…

More...

Marketwire, News, Syndication »

Quidel Reports Fourth Quarter and Full Year 2011 Financial Results

Posted by Mary Canady February 29th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Feb 29, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today financial results for the fourth quarter and full year ended…

More...